Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Phase 2CompletedNCT00326326

Pfizer84 enrolled

Overview

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Dyslipidemia

Interventions

CP-778,875DRUG

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HDL-C \< or = 45 mg/dL for men and \< or = 55 mg/dL for women * Triglycerides between 150-500 mg/dL * Fasting Plasma Glucose 140-240 mg/dL Exclusion Criteria: * Known cardiovascular, carotid, or peripheral vascular disease

Locations (31)

Outcomes

Primary Outcomes

HDL-C Safety and Efficacy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Anniston, Alabama, United States

Pfizer Investigational Site

Huntsville, Alabama, United States

Pfizer Investigational Site

Greenbrae, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Walnut Creek, California, United States

Pfizer Investigational Site

DeFuniak Springs, Florida, United States

Pfizer Investigational Site

Destin, Florida, United States

Pfizer Investigational Site

Jupiter, Florida, United States

Pfizer Investigational Site

Melbourne, Florida, United States

Pfizer Investigational Site

Atlanta, Georgia, United States

...and 21 more locations